Glucose–insulin–potassium (GIK) therapy has been investigated in adults with acute myocardial infarction for over 50 years, with proposed benefits including enhanced myocardial glucose uptake, improved contractility, anti-arrhythmic effects through membrane stabilization, and reduced free fatty acid metabolism [14]. The gene discussed is INS; the disease is myocardial infarction.